Lilly shares regulatory goals for next 2 years


Eli Lilly and Co. CEO David Ricks unveiled his company's plans to gain five drug approvals within the next two years, including its Alzheimer's disease candidate donanemab and mantle cell lymphoma drug pirtobrutinib. Other candidates Lilly expects to advance include diabetes drug tirzepatide, lebrikizumab for atopic dermatitis and mirikizumab, their ulcerative colitis candidate.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.